Lung Cancer Diagnostic Tests market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Lung Cancer Diagnostic Tests market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other Diagnostics Methods
Segment by Application
Precision Medicine
Personalized Medicine
Cancer Monitoring
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Advpharma Inc
AIT Austrian Institute of Technology GmbH
Courtagen Life Sciences Inc
DiagnoCure Inc. (Inactive)
BioMark Diagnostics Inc.
BioMarker Strategies LLC
Emory University
Epigenomics AG
GlycoZym
HalioDx SAS
Louisville Bioscience, Inc.
Mayo Clinic US
